

Neil K. Warma

Bio

Neil K. Warma



Neil Warma has been a successful healthcare entrepreneur for over 25 years having founded, managed and advised numerous biotech and pharmaceutical companies across the globe. Previously, as President and CEO of Opexa Therapeutics (NASDAQ:OPXA), a publicly traded biopharmaceutical company, he led the turnaround and rebuilding of the company's cell therapy platform and oversaw its advance through clinical development in autoimmune and orphan diseases, expansion into China and its eventual merger with Acer Therapeutics (NASDAQ:ACER). Prior to Opexa, he was CEO of Viron Therapeutics, a private biotechnology company developing novel protein-based therapeutics for cardiovascular disease and transplantation.

Mr. Warma spent several years in key management roles at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland. As Head of Global Pharma Policy and Advocacy at Novartis he worked closely on pricing, reimbursement and R&D policies. Mr. Warma also held a senior role in Global Marketing at Novartis where he worked on the launch of a GI product.

Mr. Warma also founded and later sold MedExact, a company dedicated to providing clinical and treatment information to physicians and pharmaceutical companies over the Internet. As President, he oversaw the expansion of the operations in the US, Canada and France and its sale to a large European public company.

Mr. Warma is an advisor to several companies and currently serves on the Board of Directors of several biotechnology companies and BioHouston.

Mr. Warma obtained an honors degree specializing in neuroscience from the University of Toronto and an International M.B.A. from the Schulich School of Business at York University in Toronto.